A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Melanoma · Non-small Cell Lung Cancer · Squamous Cell Carcinoma (Skin) · Renal Cell Carcinoma · Merkel Cell Carcinoma · Triple Negative Breast Cancer · Head and Neck Squamous Cell Carcinoma · Gastric Cancer/Gastroesophageal Junction Cancer · High Grade Serous Ovarian Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 120 (planned)
- Started
- Jul 29, 2025
- Main results expected
- Oct 2, 2029
- Fully finished
- Oct 2, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)
Measured over: Measured from the informed consent until Day 90 post-last dose.
Efficacy- Part 2B only (dose expansion)
Measured over: Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07115043 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC